Hims & Hers Earnings Preview: The Novo Nordisk Shift Puts GLP-1 Strategy in Focus

Unsubscribe

These AI stocks could go to zero. Here’s why. (From InvestorPlace)

Hims & Hers Earnings Preview: The Novo Nordisk Shift Puts GLP-1 Strategy in Focus

Written by Jessica Mitacek on May 8, 2026 

Hims & Hers branded weight loss kit open on a desk beside a smartphone displaying the Hims & Hers app.

Key Points

  • Following a settled legal dispute with Novo Nordisk, HIMS has transitioned from selling compounded weight-loss drugs to offering brand-name Wegovy and Ozempic.
  • While the deal was finalized in March, investors are eager to see if this pivot will boost the top line or if the financial impact likely won’t be seen until Q2.
  • Despite its recent rally, the stock remains highly volatile with short interest exceeding 35%. 
  • Special Report: The real SpaceX trade isn’t SpaceX (From Behind the Markets)

Healthcare stocks have struggled in 2026. With a year-to-date (YTD) loss of about 6%, that corner of the market has been the worst performer among all 11 sectors of the S&P 500 in 2026.

While that has been reflected in the YTD losses of some of Big Pharma’s biggest names, it has also adversely affected mid-cap stocks like telehealth platform Hims & Hers Health (NYSE: HIMS), which has fallen by more than 23% in 2026.

One day after a big announcement from the U.S. Food & Drug Administration (FDA) caused shares of HIMS to jump by nearly 4%, the stock gave it all back on Thursday, falling by nearly 5% as traders locked in profits.

But that wasn’t enough to derail the stock’s recent rally, which has seen HIMS gain nearly 32% over the past month and around 77% since its 52-week low on Feb. 27. As the company prepares to report Q1 2026 earnings on May 11, here’s what investors should watch for.

Ticker Revealed: Pre-IPO Access to “Next Elon Musk” Company (Ad)

We’ve found The Next Elon Musk… and what we believe to be the next Tesla. 

It’s already racked up $26 billion in government contracts.

Peter Thiel just bet $1 Billion on it.👉 Unlock the ticker now and get it completely free.

Is the Novo Nordisk Partnership Already Paying Off?

Following a well-publicized legal disputeearlier this year with Denmark-based Novo Nordisk (NYSE: NVO)—the eighth largest publicly traded pharmaceutical company in the world with a market cap of more than $204 billion—it’s been smooth sailing for Hims & Hers.

Since Novo Nordisk dropped its patent infringement lawsuit on March 9, HIMS has been on a tear. Not only did the Danish firm abandon its case, but it also reached a deal that allows Hims & Hers to sell Novo Nordisk’s brand-name Wegovy and Ozempic through its direct-to-consumer and virtual medical services platform.

As part of that deal, Hims & Hers agreed to stop advertising its compounded GLP-1 products, which given the FDA’s announcement that it is proposing that semaglutide, tirzepatide, and liraglutide be excluded from its 503B bulks list, could prove prescient for the company.

Wall Street will be looking for how that deal has impacted Hims & Hers’ top line. Despite the strategic shift being announced on March 9, Novo Nordisk’s GLP-1 products were not available for sale through the online platform until March 26. The books for Q1 closed on March 31, so those gross sales may not materialize on Hims & Hers’ income statement until Q2.

Will Hims & Hers Continue to Show Subscriber Growth?

The market will also be looking for confirmation that Hims & Hers’ total subscribers are holding above 2.5 million, if not steadily growing from there. That benchmark was reached near the end of 2025 and marked a more than 16% increase from the 2.2 million subscribers the company had at the end of 2024.

That growth is proving to be sustainable, after Hims & Hers ended 2023 with 1.5 million. But more important than the raw subscriber count is how the telehealth company generates 90% of its recurring revenue from its customer base.

Approximately 82% of its users remain on the platform for more than three months, and if Hims & Hers can demonstrate that it is sustainable, it should bolster full-year guidance.

Meanwhile, analysts are expecting earnings per share (EPS) of around three to four cents, which would mark an estimated 90% year-over-year decline. That may already be priced in, given the stock’s YTD performance, but a miss could accelerate selling.

The same goes for quarterly revenue, which consensus forecasts put in the range of $616 million to $619 million. Wall Street is already bracing for a “reset quarter” after revenue growth tapered from nearly 111% in Q1 2025 to less than 29% in Q4, so any surprise to the upside could spur another leg to the current rally.

The #1 stock to buy BEFORE the June S-1 filing (Ad)

When the SpaceX IPO launches, most retail investors will be locked out. The banks, funds, and insiders get in early – while everyone else waits on the sidelines.

But one small infrastructure supplier – a critical piece Musk can’t scale the Colossus network without – is still trading well under institutional radar. A new briefing reveals the name and ticker at no cost.Get the SpaceX infrastructure stock name and ticker here

Analysts Are Taking a Wait-and-See Approach

Despite an average 12-month price target of nearly $32, which implies potential upside of around 24%, Wall Street remains tepid on the stock.

Of the 17 analysts currently covering HIMS, four assign it a Buy rating, 12 assign it a Hold rating, and just one assigns it a Sell rating. Overall, the stock receives a consensus Hold rating.

Institutional ownership of nearly 64% falls within the typical range for mid-cap companies. Outflows of $1.62 billion have nearly caught up to inflows of $1.8 billion over the past 12 months after selling accelerated in Q4 2025. But that trend reversed in Q1, with institutional selling 88% lower than institutional buying.

With a high beta of 2.43, the inherently volatile stock is currently being heavily targeted by bears. Concerningly, more than 35% of the float—or nearly 70 million shares of the almost 228 million shares outstanding—is currently shorted.

Still, strong earnings could shift sentiment and propel the stock closer to the consensus analyst price target. Shareholders and prospective investors should mark their calendars for Monday, May 11, when Hims & Hers Health reports Q1 2026 results.

Read this article online ›

Read More

MarketBeat All Access is the premier all-in-one stock research solution that helps you identify the best stocks, monitor your portfolio, and keep track of the market.

Did you find this article helpful?

I liked this article.
I did not like this article.

Thank you for subscribing to TickerReport, where we work around-the-clock 
to bring you the latest market-moving news.

Contact Us  |  Unsubscribe

© 2006-2026 MarketBeat Media, LLC dba TickerReport. All rights reserved.
345 N Reid Pl., Sixth Floor, Sioux Falls, South Dakota 57103-7078. United States..

Unknown's avatar

Published by RJ Hamster

I was born on 6 August 1956 in San Francisco, California to Janet and (the late) Richard Hovis. I grew up in Santa Monica, California where I attended elementary, junior high school, and high school (graduating in 1974), in addition to involvement in sports and recreation (Little League +, the Boy’s Club ++). Further, it was in elementary school – St. Augustine’s By-the -Sea Parish School that I found, and made the choice to truly journey with God. I attended Arizona State University from 1974 to 1977 – seeking to become an architect, however, I was not accepted, and, as such, I graduated with a Liberal Arts degree. Upon graduation from Arizona State University, I attended Cal Poly San Luis Obispo and studied City and Regional Planning at the Master’s level. I successfully completed one (1) year in a two (2) year program – I did not complete the Master’s degree in City and Regional Planning – due to personal reasons. I returned to Santa Monica where I started (October 1979) my career as graphic designer with Exxon Company, USA. I spent five years with Exxon Company, USA. While working with Exxon Company, USA I was accepted into architectural school – Sci-Arc in Southern California, however, I did not attend preferring to stay with Exxon.. In 1982 I married Laura Flosi and in April 1983 we had our one and only child – Lauren Alain Hovis – a gift from God. We moved to Phoenix, Arizona in 1984 from Los Angeles, where I went to work as a graphic designer with Kitchell CEM (from 1985 -1987). From 1987 – 1995 I was an independent contractor, and a registered representative in mortgage finance, financial management, graphic design, and drafting. Further, I attended the University of Phoenix and successfully obtained a Master’s in Business Administration (MBA) in 1982. I was also a member of the Scottsdale Jaycees, where I became very involved in community events and projects. In 1994, I accepted a cartography position with the Defense Mapping Agency in Reston, Virginia. As such, I relocated from Phoenix to Reston. In 1998, I was accepted and worked as a Visual Information Officer with the Central Intelligence Agency. In 2002, I worked as a Support Officer until my retirement (due to a need for shoulder surgery) in September 2018. Away from my Federal Government service, I have been involved in various organizations and activities in Northern Virginia. In November of 2011, I married Rebecca Ouellette in Santa Monica, California. I reside in San Tan Valley, AZ with my two hamster - Jess and Timothy, our fish, our lizard - RJ Lizard., and our cats - Pearl and Grey. As to hobbies, I enjoy playing sports, attending sporting events, mentoring individuals from financial management to hamsters, building models, photography, travel, multimedia design, managing partner for RJ Hamster, and jazz – smooth jazz to a samba or a bossa nova. Love and God Bless, Peter – aka RJ Hamster Jo hi

Leave a Comment